Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $2.55 million. The enterprise value is -$3.59 million.

Market Cap	2.55M
Enterprise Value	-3.59M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025, after market close.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

DRMA has 2.04 million shares outstanding. The number of shares has increased by 486.90% in one year.

Current Share Class	2.04M
Shares Outstanding	2.04M
Shares Change (YoY)	+486.90%
Shares Change (QoQ)	+129.79%
Owned by Insiders (%)	52.80%
Owned by Institutions (%)	0.78%
Float	343,415

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.44
P/TBV Ratio	0.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.44

Current Ratio	3.44
Quick Ratio	3.16
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -202.20% and return on invested capital (ROIC) is -129.32%.

Return on Equity (ROE)	-202.20%
Return on Assets (ROA)	-102.89%
Return on Invested Capital (ROIC)	-129.32%
Return on Capital Employed (ROCE)	-243.24%
Revenue Per Employee	n/a
Profits Per Employee	-$1.41M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.17% in the last 52 weeks. The beta is 0.67, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-81.17%
50-Day Moving Average	1.24
200-Day Moving Average	1.95
Relative Strength Index (RSI)	52.68
Average Volume (20 Days)	465,740

Short Selling Information

The latest short interest is 294,210, so 14.42% of the outstanding shares have been sold short.

Short Interest	294,210
Short Previous Month	138,242
Short % of Shares Out	14.42%
Short % of Float	85.67%
Short Ratio (days to cover)	0.47

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-11.53M
Pretax Income	-9.82M
Net Income	-11.27M
EBITDA	n/a
EBIT	-11.53M
Earnings Per Share (EPS)	-$15.02

Balance Sheet

Cash & Cash Equivalents	6.14M
Total Debt	n/a
Net Cash	6.14M
Net Cash Per Share	$3.01
Equity (Book Value)	4.74M
Book Value Per Share	2.83
Working Capital	4.74M

Cash Flow

Operating Cash Flow	-9.40M
Capital Expenditures	n/a
Free Cash Flow	-9.40M
FCF Per Share	-$4.60

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-486.90%
Shareholder Yield	-486.90%
Earnings Yield	-441.81%
FCF Yield	-368.36%

Analyst Forecast

The average price target for DRMA is $6.00, which is 380.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.00
Price Target Difference	380.00%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on May 16, 2024. It was a reverse split with a ratio of 0.0666667:1.

Last Split Date	May 16, 2024
Split Type	Reverse
Split Ratio	0.0666667:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1